Short answer
Beam Therapeutics Inc. (BEAM) filed an 8-K current report with the SEC on June 8, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders re-elected John Evans, John Maraganore, and Christi Shaw as Class III directors through the 2029 annual meeting.
Beam Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Shareholders re-elected John Evans, John Maraganore, and Christi Shaw as Class III directors through the 2029 annual meeting
- Deloitte & Touche LLP ratified as independent auditor for fiscal year ending December 31, 2026
- Executive compensation approved on an advisory basis, with 71,546,749 votes for and 985,066 against
- Director elections included 13,419,659 broker non-votes, limiting interpretation of shareholder support percentages
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Beam Therapeutics Inc. 8-K filings
Get the next BEAM 8-K as it lands
Follow BEAM for push alerts, or ask the research agent what this filing means.